HC Wainwright Issues Optimistic Outlook for TARS Earnings

Key Points

• HC Wainwright raised its Q3 EPS forecast for Tarsus Pharmaceuticals from ($0.35) to ($0.32), maintaining a "Buy" rating with a price target of $72.00.
• Tarsus Pharmaceuticals reported a Q2 earnings miss with EPS at ($0.48), below the consensus estimate of ($0.33), although revenue of $102.66 million exceeded expectations.
• Institutional investors own approximately 90.01% of Tarsus Pharmaceuticals' stock, indicating strong institutional backing.

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) - Equities researchers at HC Wainwright increased their Q3 2025 EPS estimates for Tarsus Pharmaceuticals in a report issued on Thursday, August 7th. HC Wainwright analyst M. Caufield now forecasts that the company will earn ($0.32) per share for the quarter, up from their prior estimate of ($0.35). HC Wainwright has a "Buy" rating and a $72.00 price objective on the stock. The consensus estimate for Tarsus Pharmaceuticals' current full-year earnings is ($3.17) per share. HC Wainwright also issued estimates for Tarsus Pharmaceuticals' Q4 2025 earnings at ($0.14) EPS, FY2025 earnings at ($1.56) EPS, FY2026 earnings at ($2.15) EPS and FY2028 earnings at $0.30 EPS.

A number of other brokerages also recently weighed in on TARS. The Goldman Sachs Group upped their target price on Tarsus Pharmaceuticals from $46.00 to $51.00 and gave the company a "neutral" rating in a report on Monday, May 5th. Wall Street Zen downgraded Tarsus Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Thursday, May 22nd. Oppenheimer assumed coverage on Tarsus Pharmaceuticals in a report on Monday, June 2nd. They issued an "outperform" rating and a $75.00 price objective on the stock. Finally, Guggenheim increased their price objective on Tarsus Pharmaceuticals from $78.00 to $84.00 and gave the stock a "buy" rating in a report on Friday, May 2nd. Two research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Tarsus Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average target price of $66.67.

Tarsus Pharmaceuticals Stock Up 2.1%

Shares of TARS traded up $1.06 during trading hours on Monday, reaching $52.42. The company's stock had a trading volume of 504,136 shares, compared to its average volume of 660,621. The firm has a market cap of $2.21 billion, a price-to-earnings ratio of -22.50 and a beta of 0.79. Tarsus Pharmaceuticals has a 1-year low of $24.95 and a 1-year high of $57.28. The company has a quick ratio of 5.21, a current ratio of 5.26 and a debt-to-equity ratio of 0.22. The company has a 50 day moving average of $41.82 and a two-hundred day moving average of $45.71.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The company reported ($0.48) EPS for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.15). The firm had revenue of $102.66 million for the quarter, compared to analysts' expectations of $95.81 million. Tarsus Pharmaceuticals had a negative net margin of 31.13% and a negative return on equity of 32.36%.

Institutional Trading of Tarsus Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of the company. Quantbot Technologies LP lifted its stake in shares of Tarsus Pharmaceuticals by 151.8% in the second quarter. Quantbot Technologies LP now owns 40,339 shares of the company's stock worth $1,634,000 after buying an additional 24,319 shares during the last quarter. Virtus Investment Advisers LLC lifted its stake in shares of Tarsus Pharmaceuticals by 54.5% in the second quarter. Virtus Investment Advisers LLC now owns 10,852 shares of the company's stock worth $440,000 after buying an additional 3,827 shares during the last quarter. Norges Bank acquired a new stake in shares of Tarsus Pharmaceuticals in the second quarter worth $19,095,000. Quadrature Capital Ltd acquired a new stake in shares of Tarsus Pharmaceuticals in the second quarter worth $588,000. Finally, Russell Investments Group Ltd. lifted its stake in shares of Tarsus Pharmaceuticals by 7.9% in the second quarter. Russell Investments Group Ltd. now owns 145,240 shares of the company's stock worth $5,884,000 after buying an additional 10,623 shares during the last quarter. 90.01% of the stock is currently owned by institutional investors and hedge funds.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.